Rationale: Smoking cessation counseling in conjunction with lowdose computed tomography (LDCT) lung cancer screening is recommended in multiple clinical practice guidelines. The best approach for integrating effective smoking cessation interventions within this setting is unknown.
Overview
Smoking cessation counseling and treatment are critical corollaries to low-dose computed tomography (LDCT) screening, offering an opportunity to reduce smokingrelated mortality. Although the Centers for Medicare and Medicaid Services (CMS) requires that smoking cessation interventions be delivered in conjunction with lung cancer screening for Medicare reimbursement of LDCT screening, neither the most effective interventions nor the best approach for implementing those interventions with demonstrated efficacy in this setting is known. This research policy statement identifies consensus prioritization of diverse stakeholders regarding three topics for research on smoking cessation interventions in the context of LDCT screening: (1) target population to study; (2) adaptation, development, and testing of potential interventions; and (3) implementation of interventions with demonstrated efficacy. In each of these three domains, we summarize the existing evidence; identify research gaps; and, on the basis of a formal process of consensus development, prioritize research questions. The fourth section presents our committee's recommendations for standardized tools and measures to use in conducting this research. This statement offers a research agenda to inform investigators as well as governmental and nongovernmental funding agencies to generate high-priority, high-quality research surrounding integration of tobacco dependence treatment with LDCT screening.
Key Conclusions and Recommendations
Population domain.
d Although there was little consensus on which questions within the population domain were of the highest priority, research in this area should consider addressing how LDCT screening results (positive or negative test results) affect motivation to quit and the resultant impact on effectiveness of cessation, because it was ranked highest by stakeholder representatives.
Intervention domain.
d There is little data on the effectiveness of smoking cessation interventions in the LDCT screening setting, leaving significant knowledge gaps regarding the optimal method of smoking cessation counseling, timing of delivery, and pharmacotherapy approaches in this context. d Research to evaluate the effectiveness of established, evidence-based interventions for smoking cessation in lung cancer screening settings ranked highest among stakeholder representatives.
Implementation domain.
d There is scant data on the implementation of smoking cessation interventions into lung cancer screening programs. d A national research agenda should include strategies for implementing tobacco dependence treatment within the lung cancer screening setting. d Stakeholders prioritized determining the system barriers to integrating smoking cessation in lung cancer screening settings, as well as researching effective strategies to overcome these barriers.
Standardized tools and measures.
d There was strong consensus among committee members that using standardized tools, measures, and outcomes in this research would increase the quality of the science and the ability to interpret and pool results of different studies. d Applicable standardized measures and tools are outlined in this statement to provide scientists the tools with which to conduct high-quality research in this setting.
Introduction
Lung cancer is the leading cause of cancer death in the United States (1, 2) . Over 90% of lung cancer deaths would be avoided if Americans never initiated cigarette smoking. Quitting smoking is the most effective intervention to reduce lung cancer mortality (3, 4) ; yet, approximately 36.5 million Americans continue to smoke cigarettes (2, 5) . Current smokers between the ages of 55 and 64 years would gain 4 years of life expectancy from avoided lung cancer and other tobacco-related deaths if they quit smoking (6) . Among current smokers, the number needed to intervene is as low as 77 because providing cessation interventions to 11 individuals leads to at least 1 additional successful quitter (7), and depending on age and sex, 1 early death from all tobacco-related causes can be avoided by helping as few as 7 individuals quit smoking, even among middle-aged and older adults (8) . Despite the fact that nearly 70% of current smokers attempt to quit each year, only 1 to 6% of smokers are successful in quitting (9, 10) . The other intervention proven to reduce lung cancer mortality is annual LDCT screening of middle-aged and older smokers with a substantial history of tobacco use, which is associated with a gain of 0.04 years of life expectancy from avoided lung cancer deaths (11, 12) . The number needed to screen is 320 to prevent 1 early lung cancer death (11, 12) . In the NLST (National Lung Screening Trial), individuals in the LDCT screening arm who successfully quit smoking had the lowest rate of lung cancer deaths (13) . Thus, providing smoking cessation treatment in conjunction with LDCT screening offers an opportunity to combine two interventions known to reduce smoking-related morbidity and mortality.
Recognizing the importance of helping adults quit smoking, the CMS requires that smoking cessation interventions be offered to receive Medicare reimbursement of LDCT screening. Similarly, multiple professional organizations and the U.S. Preventive Services Task Force recommend that smoking cessation interventions be delivered in conjunction with LDCT screening (14) . Yet, neither the most effective interventions nor the best approach for implementing those interventions with demonstrated efficacy in this setting is known.
The National Institutes of Health (NIH); the National Academies of Science, Engineering, and Medicine; the Association for the Treatment of Tobacco Use and Dependence; and the Society for Research on Nicotine and Tobacco have all highlighted the need for research on optimal strategies to integrate smoking cessation interventions within LDCT screening programs (15) (16) (17) . In this research statement, we discuss the methodology and development of a stakeholder-endorsed research priority agenda relating to tobacco dependence treatment in LDCT screening programs.
Methods
The committee chair (H.K.) and cochair (R.S.W.) convened a team with expertise in AMERICAN THORACIC SOCIETY DOCUMENTS LDCT screening and/or tobacco dependence treatment (Table 1) . The team included multiple stakeholders representing the perspectives of scientists conducting translational, clinical, cost-effectiveness, implementation science, and health services research; governmental and nongovernmental funding agencies; professional societies; clinicians (physicians, nurses, and health educators specializing in pulmonary medicine, thoracic surgery, and/or tobacco dependence treatment); and patients. To understand diverse contexts and strategies for implementing smoking cessation treatment within LDCT screening programs, we selected individuals representing various clinical settings, including academic centers, community hospitals, integrated health systems, and the Veterans Health Administration. Potential conflicts of interest were disclosed and managed in accordance with the policies and procedures of the American Thoracic Society (ATS).
Our committee met in person at the May 2016 ATS International Conference. Designated moderators led group discussions on four topics: the effect of screening on smoking cessation, interventions for smoking cessation in the LDCT screening setting (not including interventions at the policy level), implementation of smoking cessation interventions in the LDCT screening setting, and standardized tools and measures to conduct research on smoking cessation interventions in the setting of LDCT screening. For each of these topics, the moderator summarized the existing evidence (based on primary literature and recent systematic reviews) and identified critical gaps. Through discussion, the committee compiled several draft research questions in three areas: (1) target population to study; (2) adaptation, development, and testing of potential interventions; and (3) implementation of interventions with demonstrated efficacy. For the fourth topic, we discussed existing tools and measures to conduct high-quality research on smoking cessation and compiled lists of resources for investigators working in this area.
Following the in-person meeting, the chairs further refined the draft research questions to eliminate redundancy, with assistance from committee members. We then came to consensus through group discussion on 7 questions in each of the three topics (21 questions total) to be posed to a larger group of stakeholder representatives (Table 1) for prioritization through a subsequent online survey. We identified stakeholders with expertise in tobacco dependence treatment, inviting all members of the ATS Tobacco Action Committee as of August 1, 2016. We also identified stakeholders with expertise in LDCT screening by recruiting from among experts who participated in the July 2016 National Academies of Science, Engineering, and Medicine Workshop on Implementation of Lung Cancer Screening. Finally, stakeholders with expertise in both tobacco dependence treatment and LDCT screening were identified by chairs and committee members and invited to participate in the online survey. In total, 77 stakeholders, who included representatives from payers, government and nongovernment agencies, patient advocacy groups, funding agencies, academic hospitals, government hospitals, integrated health systems, and physician and nonphysician professional organizations, were invited to participate in the online survey. Including our committee members, a total of 43 participants (56%) participated in the online survey (Table 1) . Each stakeholder was asked to rank topics from 1 (most important) to 7 (least important) in each of the three topic areas, with no ties between questions within a given topic area (i.e., each question had to be assigned a unique rank). The final prioritization of questions was generated hierarchically on the basis of average rank assigned (lowest to highest).
The chairs drafted the initial version of the manuscript of this document with assistance from committee members. The manuscript was circulated to the full committee and iteratively revised. The final document was approved by the ATS Board of Directors.
Results
The results are organized into four sections designed to help scientists and funding agencies conduct and assess research related to integration of smoking cessation interventions with LDCT screening. The first three sections correspond to the three topics in which questions were prioritized: (1) target population to study; (2) adaptation, development, and testing of potential interventions; and (3) implementation of interventions with demonstrated efficacy. The fourth section presents our committee's recommendations for standardized tools and measures to conduct this research.
Target Population to Study (Who?)
Summary of evidence and research gaps.
The existing literature provides a rationale for studying smoking cessation interventions in specific populations. Within the NLST, current smokers, those with less than a high school education, and black individuals had higher rates of lung cancer death (13) . Certain groups, including socioeconomically disadvantaged groups, individuals with comorbid substance use or psychiatric disorders, and certain racial and ethnic minorities, are less likely to be offered, to use, and to successfully complete evidence-based tobacco dependence treatment (10, (18) (19) (20) . It has been suggested that LDCT screening may provide a "teachable moment" for these underserved smokers and an opportunity to offer smoking cessation interventions at a time when these individuals are more cognizant of the potential harms of smoking and thus more likely to be receptive to interventions (21, 22) .
Recommendations and clinical practice guidelines to date have not consistently endorsed the allocation of intervention resources to subgroups of smokers on the basis of patient factors such as motivation to quit or self-efficacy. In the Danish Lung Cancer Screening Trial, higher motivation to quit at baseline predicted smoking status both 1 year after screening and at the end of a 5-year screening program (23, 24) . Several other factors, such as older age, poorer lung function, greater perceived advantages of quitting, and higher self-efficacy, were associated with abstinence at 1 year (23, 25) . Historically, providers and quitlines have been encouraged to identify a patient's willingness to quit and provide cessation treatment only to those patients who have a clear intent to quit (26) . However, recent trials have suggested that providing cessation treatment to all smokers, regardless of their current willingness to quit, may help more smokers quit (26) .
Other populations that may be of particular interest for study are defined by the results of LDCT screening. Two recent AMERICAN THORACIC SOCIETY DOCUMENTS systematic reviews showed that undergoing LDCT screening in itself is not sufficient to achieve long-term smoking abstinence (27, 28) . On one hand, however, there is some evidence that positive LDCT screening results (e.g., detection of nodules) are associated with increases in quit rates and in reducing relapse among recent quitters (23, 24, 27, 29 There is little data on the effectiveness of smoking cessation interventions in the LDCT screening setting (25, (34) (35) (36) (37) (38) (39) , leaving significant knowledge gaps regarding the optimal method of smoking cessation counseling, timing of delivery, and pharmacotherapy approaches in this context. Overall, in screened patients, more intensive interventions appeared to be associated with greater improvement in 6-month smoking abstinence and readiness to quit. In one retrospective case-control study analyzing selfreported physician interventions and quit rates by NLST participants, using the U.S. Public Health Service-recommended "5 A's" approach, the "assist" (connecting smokers with evidence-based treatment) and "arrange follow-up" steps increased the odds of quitting by 40 and 46%, respectively (25) . To our knowledge, no studies to date have evaluated the utility and safety of novel approaches such as electronic nicotine delivery systems as a bridge to quitting, financial incentives, mobile technology-based interventions, or patient navigation for smoking cessation in the context of LDCT screening. Prioritization of research questions. Of the 43 stakeholders, 36 ranked seven questions relating to "intervention to study." Final voting results indicated that researching "the effectiveness of established, evidence-based interventions for smoking cessation in lung cancer screening settings" was a strong priority based on stakeholder rankings in this area (mean score, 2.86; possible range, 1 = most important to 7 = least important) ( Table 3) . By contrast, the lowest-ranked question, "What is the optimal intensity of smoking cessation interventions in lung cancer screening setting? What is the comparative effectiveness of interventions that vary in intensity?" received a ranking of 5.03.
Implementation of Interventions with Demonstrated Efficacy (How?)
There is scant data on the implementation of smoking cessation interventions into LDCT screening programs; this has been identified as an area for further research (40) (41) (42) . LDCT screening programs vary in terms of resources and referral pathways for providing smoking cessation interventions. A recent national survey suggested that most LDCT screening programs do not currently offer guideline-based tobacco dependence treatment (42) . For example, NLST participants reported that their primary care providers only partially followed the U.S. Public Health Service-recommended "5 A's" recommendations: Whereas the majority "asked," "advised," and "assessed," only half "assisted" smokers in connecting to treatment, and only 10% "arranged follow-up" (25) . Little research has been done to explore the barriers to, facilitators of, and most effective implementation strategies for delivering smoking cessation interventions in the LDCT screening setting.
Prioritization of research questions. Of 43 stakeholders, 35 ranked seven questions relating to implementation. Final voting results indicate that "What are the system barriers to integrating smoking cessation in lung cancer screening settings, and what are the effective strategies to overcome these barriers?" and "What are effective strategies for implementing, disseminating, and scaling up cessation interventions in the real world?" received similar priority rankings (3.06 and 3.17, respectively), with little separation in priority scores between the two (Table 4) . By contrast, the lowest-ranked topic had a priority score of 5.49.
Standardized Tools and Measures to Conduct High-Quality Research
There was strong consensus among committee members that using standardized tools, measures, and outcomes in this research would increase the quality of the science and the ability to interpret and pool results of different studies. Other professional organizations have issued recommendations about measures of tobacco abstinence and biochemical confirmation in conducting trials of smoking cessation interventions, which our committee agreed would be applicable in the context of LDCT screening as well. [44] , and the SCALE Collaboration) agree that abstinence from tobacco use is the most important outcome to measure when evaluating the clinical effectiveness of a smoking cessation intervention. Outcomes measured at a longer duration from the intervention (e.g., 6-mo or 1-yr quit rates) are considered more robust than outcomes measured at a shorter interval (e.g., 1-mo quit rates). When feasible, biochemical confirmation should be obtained. Biochemical markers include cotinine, carbon monoxide, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), or anabasine and anatabine (Table 5) .
Use of standardized measures of exposures is also important for interpretation of research results in smoking cessation trials. The National Human Genome Research Institute, with cofunding by the National Institute on Drug Abuse, has developed a publicly available Web-based resource, the PhenX Toolkit (www.phenxtoolkit.org) (51), which compiles high-quality standard measures of phenotypes and environmental exposures for use in biomedical research. How do site characteristics impact the effectiveness of cessation interventions in lung cancer screening? Examples of site characteristics include comprehensive screening programs versus ad hoc screening, sites that permit self-referral compared with those that accept only provider-referred patients, reimbursement for cessation, and demographics and case mix of patients served.
11.4%
Definition of abbreviation: EMR = electronic medical record. Table E2 . Study design is an important consideration when generating high-quality research. Although the randomized controlled trial are the only study design that can be used to measure efficacy directly, observational designs may be particularly useful in evaluating smoking cessation interventions. For example, randomized controlled trial participants must have enough desire to enroll in the trial, potentially limiting generalizability to the many patients who are not currently interested in quitting. The ATS developed a statement on comparative effectiveness research that may help researchers and funders decide when nonrandomized designs may be most helpful in smoking cessation studies (52) .
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SRNT (43):
A workgroup formed by the Society for Research on Nicotine and Tobacco (SRNT) reviewed the literature on abstinence measures used in trials of smoking cessation interventions and recommended that trials report on multiple measures of abstinence, with a minimum of the following:
• Report prolonged abstinence (i.e., sustained abstinence after an initial period in which smoking is not counted as a failure) as the preferred measure, plus point prevalence as a secondary measure • Use 7 consecutive days of smoking or smoking on ≥1 day of 2 consecutive weeks to define treatment failure • Include non-cigarette tobacco use, but not nicotine medications in definitions of failure • Report results from survival analysis to describe outcomes more fully. The SRNT task force recommends additional considerations in certain circumstances:
• Trials of smokers willing to set a quit date: Follow-ups should be tied to the quit date and 6-and/or 12-month abstinence rates should be provided.
An initial 2-week grace period for prolonged abstinence definitions; however, the period may vary, depending on the presumed mechanism of the treatment.
• Trials of smokers who may not be currently trying to quit:
Follow-up should be tied to the initiation of the intervention and should report a prolonged abstinence measure of ≥6-month duration and point prevalence rates at 6-and 12-month follow-ups.
The grace period for these trials will depend on the time necessary for treatment dissemination, which will vary depending on the treatment, setting, and population.
• Trials that use short-term follow-ups (≤3 months) to demonstrate possible efficacy:
A prolonged abstinence measure of ≥ 4 weeks should be reported. Recommend a 2-week grace period; however, that period can vary.
Russell Standard (RS) criteria (44):
Applicable to trials of cessation aids where participants have a defined target quit date and there is face to face contact with researchers or clinic staff.
Where there is no face to face contact with participants, the requirement for biochemical verification may be impracticable but the other criteria outlined below should still apply.
• Follow up for 6 months or 12 months from the target quit date or the end of a pre-defined grace period • Self-report of smoking abstinence over the whole follow-up period allowing up to 5 cigarettes in total.
• Biochemical verification of abstinence at least at the 6-month or 12-month follow up point.
• Use of an intention to treat approach in which data from all randomized smokers are included in the analysis unless they have died or moved to an untraceable address (participants who are included in the analysis are counted as smokers if their smoking status at the final follow-up cannot be determined) • Following up protocol violators and using their true smoking status in the analysis • Collecting follow up data blind to smokers' allocation to trial groups In comments and discussions with voting members, researching how LDCT screening results affect motivation to quit, as well as the resultant impact on effectiveness of cessation, was prioritized within the population domain because it is likely to influence how screening providers communicate with patients about their results and provide messages about smoking cessation. Whereas the CMS highlights the importance of integrating smoking cessation counseling in the initial shared decision-making conversation about screening, the voting members highlighted that post-screening messaging and interventions related to smoking cessation may also be a critical priority.
Within the intervention domain, the topic of developing an evidence base for understanding how established interventions that have been demonstrated to be effective in other settings perform in the LDCT screening context was prioritized in part because screening providers are eager to ensure that the cessation interventions they provide are effective in this setting. Many voting members emphasized that providing the most effective care possible is a priority and should be guided as much as possible by research evidence. Within the implementation domain, stakeholders identified that a clear challenge to increasing smoking cessation within the LDCT screening setting is ensuring that evidence-based interventions are fully implemented. As highlighted by Park and colleagues, less than 10% of providers fully provided cessation services, in part because of limitations of clinician time and resources (25) . To maximally reduce lung cancer mortality, it is critical to overcome barriers to referring high-risk smokers for both LDCT screening and tobacco dependence treatment and to support implementation of full-service LDCT screening programs capable of providing evidence-based tobacco dependence treatment.
Stakeholders were more consistent across rankings for the domains of intervention and implementation, in each case prioritizing one or two questions as clear priorities, whereas rankings were more widely dispersed across the questions within the population domain. Of note, multiple stakeholders contacted the chairs to comment on how difficult it was to rank these questions because they considered all of them important, and not all stakeholders ranked questions in all domains, which may similarly indicate difficulty in assigning relative priority to the questions. Nonetheless, each topic represents the consensus prioritization of diverse stakeholders and provides an agenda for research on smoking cessation interventions in the context of LDCT screening.
This research is urgently needed, as recognized by multiple organizations, including the NIH and the National Academies of Science, Engineering, and Medicine (17, 53) . The NCI recently awarded six R01 grants to develop and test smoking cessation interventions for current smokers undergoing LDCT lung cancer screening (45, 53) . The standardized measures and approaches outlined in this document provide scientists the tools with which to conduct high-quality studies using a variety of methods (explanatory trials, pragmatic trials, mixed methods, comparative effectiveness) to answer these questions and to assess mechanisms through which intervention effects may occur (mediators such as psychological characteristics, perceived lung cancer risk, self-efficacy/confidence to quit). This statement provides a road map for scientists and government and nongovernment funding agencies to use in generating high-priority, high-quality research to answer pressing questions surrounding integration of tobacco dependence treatment within LDCT screening screenings. We hope this statement will stimulate the research needed to provide answers to clinicians and administrators seeking to deliver effective smoking cessation interventions to smokers undergoing LDCT screening, thereby improving care and ultimately reducing lung cancer mortality. n This official research statement was prepared by an ad hoc subcommittee of the Assembly on Thoracic Oncology. R.A.S., and S.B.Z. reported no relationships with relevant commercial interests.
